Floatz logo

Linaclotide

Healthy, no Evidence of Disease

Mayo Clinicprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Healthy, no Evidence of Disease cohort.

Asset / SponsorPhaseRating
Cediranib
Mayo Clinic
Phase 1CCC
Letrozole
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Linaclotide is also rated in:

opioid-induced constipationDormant
B
Indicative ·
57 / 100
View asset →
colorectal adenomaDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →